Results 161 to 170 of about 36,503 (286)
Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 337-342, August 2025.Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a ...
Chad A. Bousman +14 more
wiley +1 more source
The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole [PDF]
, 2002 C. H. J. BEKKERS +3 more
openalex +1 more source
MedComm, Volume 6, Issue 8, August 2025.ABSTRACT Hepatocellular carcinoma (HCC) is a deadly disease characterized by a high mortality rate and resistance to conventional therapies, highlighting the need for novel therapeutic interventions. Given the multifaceted nature of HCC pathogenesis, a multitargeted and polypharmacological approach is crucial for effective treatment. This study reports
Shakeel Ahmad Khan +4 more
wiley +1 more source
Current State of Pharmacogenomic Implementation Into Care for Persons With Cystic Fibrosis
Pediatric Pulmonology, Volume 60, Issue 8, August 2025.ABSTRACT Cystic fibrosis (CF) was once a fatal disease of childhood, but with advances in combination CFTR modulator therapies, life expectancy for persons with CF (PwCF) has increased. Despite remarkable improvements in life expectancy, CF is a chronic multiple organ system disease and comorbidities characterized by recurrent respiratory infections ...
Emma M. Tillman +3 more
wiley +1 more source
Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2‐receptor antagonist [PDF]
, 2003 T. Shimatani +5 more
openalex +1 more source
Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
Alimentary Pharmacology &Therapeutics, Volume 62, Issue 4, Page 400-418, August 2025.Most therapies used in inflammatory bowel disease appear safe and effective when used in chronic kidney disease including on renal replacement therapy, particularly biologic therapies. Some caution should be considered when using conventional therapies and JAK inhibitors.
Lynna Chen +6 more
wiley +1 more source
Basic &Clinical Pharmacology &Toxicology, Volume 137, Issue 2, August 2025.ABSTRACT Classifications of drug interaction alerts regarding clopidogrel and a proton pump inhibitor (PPI) differ between knowledge resources. In this systematic review, Medline, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) applying PICO criteria: P = patients on clopidogrel; I = intervention: PPI (subgroup ...
Magnus A. B. Axelsson +3 more
wiley +1 more source
Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations [PDF]
, 2003 Aurel Constant Allabi +4 more
openalex +1 more source
Synthesis of New Glycometronidazole Compounds With Antifungal and Antifungal Biofilm Activity
Chemical Biology &Drug Design, Volume 106, Issue 2, August 2025.Novel glyco‐triazole‐metronidazole compounds obtained via a click chemistry reaction—used as antifungal and antifungal biofilm agents. Subsequent antifungal tests showed good results for a number of compounds which are believed to essentially function as a bioactive “Trojan horse.” ABSTRACT Carbohydrates are well known to be one of the most abundant ...
Rayssa de Cassia Alves Iemini +9 more
wiley +1 more source